Clinical Performances of 3-different Tooth-colored Restorative Materials in Class-II Cavities
NCT ID: NCT06211582
Last Updated: 2025-12-05
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
47 participants
INTERVENTIONAL
2022-08-28
2025-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Performance of Novel Alkasite Restorative Material "Cention Forte" in Class II Restorations
NCT06833528
Trial With Two New Tooth-colored Restorative Materials in Class I/II Cavities
NCT05748327
Clinical Performance of a Glass-ionomer Restorative System in Extended-sized Cavities
NCT02991664
Comparison of Bulk-Fill Composite Resins in Class II Restorations
NCT06212141
Clinical Performance of a Highly-filled Flowable Composite in Class III Restorations.
NCT07051551
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Restorative materials with bioactive or caries-protective abilities have been introduced, such as glass hybrid materials. Recently, to overcome the limitations of restorative materials, it was attempted to add caries-protective ions, especially alkaline and alkaline earth ions, such as calcium, in addition to phosphate or fluoride. This newly introduced material contains alkalizing properties due to the release of hydroxyl ions.
In 2016, Ivoclar Vivadent developed a new restorative material consisting of a powder and a liquid part and commercially named this product "Cention N".
Cention N has bioactive properties like glass ionomer cements. It has been developed to prevent demineralisation by neutralising acids through ion release. It contains alkaline fillers. Therefore, a new classification as "Alkasites" has emerged.
One lesion in each patient will be randomly assigned to be restored using either the GC Gradia Direct Posterior, Cention N and Equia Forte HT. The adhesive, GC Solare Universal Bond will be used for adhesive procedures. The clinical procedure for the restorations will be performed by a single operator. The restorations will be evaluated by two calibrated examiners at baseline and at 6, 12, months in accordance with the FDI criteria. Data will be statistically analyzed using the Chi-square and Fischer's exact tests (p \< 0.05).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cention N (Ivoclar Vivadent, Schaan, Liechtenstein)
Powder: Calcium-fluoro-silicate glass, barium glass, calcium-barium-aluminium fluoro-silicate glass, iso-fillers, ytterbium trifluoride, initiators and pigments. Liquid: Dimethacrylates, initiators, stabilizers, additives and mint flavour. The mixing ratio was 2 parts powder and 2 drops of liquid or 3 parts powder and 3 drops.After distributing the powder and liquid side by side on a mixing pad, the liquid was spread to expand the surface.The first part of the powder was mixed with the entire liquid dispensed on the mixing pad.After the components have been thoroughly mixed, add the remaining powder and stirred again until a homogeneous consistency is obtained (45 - 60 seconds). After careful adaptation to the cavity and densification, occlusal excesses were removed.
Cention N (Ivoclar Vivadent, Schaan, Liechtenstein)
The Alkasite-Based Tooth-Colored Material
Equia Forte HT ( GC, Tokyo, Japan)
Powder: 95% strontium fluoroalumino-silicate glass. Liquid: 5% polyacrilic acid.
Equia Forte HT was mixed in a capsule (10 seconds) and injected into the cavity. After a 2.5 min curing time, occlusal excesses were removed. Equia Coat (GC, Tokyo, Japan) was then applied and light-cured (D-Light Pro, GC, Tokyo, Japan 1,400 mW/cm2) for 20 seconds.
Equia Forte HT ( GC, Tokyo, Japan)
Glass Hybrid Restorative Material
Gradia Direct Posterior ( GC, Tokyo, Japan)
Matrix: Urethanedimethacrylate (UDMA), dymethacrylate camphorquinone. Filler: fluoro-alumino-silicate glass silica powder.
After completing the cavity, the enamel surface was selectively roughened using 37% orthophosphoric acid for 30 seconds. Subsequently, GC Solare Universal Bond adhesive agent (GC Corp., Tokyo, Japan) was utilized. It was applied in 2mm layers in accordance with the composite manufacturer's instructions. Each layer was polymerized for 20 seconds.
Gradia Direct Posterior ( GC, Tokyo, Japan)
Conventional Composite Resin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cention N (Ivoclar Vivadent, Schaan, Liechtenstein)
The Alkasite-Based Tooth-Colored Material
Equia Forte HT ( GC, Tokyo, Japan)
Glass Hybrid Restorative Material
Gradia Direct Posterior ( GC, Tokyo, Japan)
Conventional Composite Resin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Individuals between the ages of 18-65
* Brushing your teeth twice a day
* Having at least 20 teeth in occlusion and at least 3 approximal lesions with antagonist teeth in the opposite arch
* Volunteer individuals who agree to participate in the research and sign the informed consent form and who have undergone initial periodontal treatment will be included in the study.
Exclusion Criteria
* Individuals with advanced periodontal disease
* Individuals using removable partial dentures
* Individuals with bruxism
* Individuals with malocclusion
* Patients with known allergies to resin-based restorative materials and bonding agents
* Patients with a history of allergy to local anesthesia
* Endodontic treatment, teeth that need pulp capping or endodontic treatment is available
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hacettepe University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kemal Işıklı
Principal Investigator, Research Assistant
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Filiz Yalçın Çakır, Prof.
Role: PRINCIPAL_INVESTIGATOR
Hacettepe University
Uzay Koç Vural, Assoc. Prof.
Role: PRINCIPAL_INVESTIGATOR
Hacettepe University
Kemal Işıklı
Role: PRINCIPAL_INVESTIGATOR
Hacettepe University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hacettepe University
Ankara, Ankara, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Gurgan S, Kutuk ZB, Yalcin Cakir F, Ergin E. A randomized controlled 10 years follow up of a glass ionomer restorative material in class I and class II cavities. J Dent. 2020 Mar;94:103175. doi: 10.1016/j.jdent.2019.07.013. Epub 2019 Jul 25.
Bektas Donmez S, Uysal S, Dolgun A, Turgut MD. Clinical performance of aesthetic restorative materials in primary teeth according to the FDI criteria. Eur J Paediatr Dent. 2016 Sep;17(3):202-212.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KA-22015
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.